SG11201907923VA - Anti oligosaccharide antibody - Google Patents

Anti oligosaccharide antibody

Info

Publication number
SG11201907923VA
SG11201907923VA SG11201907923VA SG11201907923VA SG11201907923VA SG 11201907923V A SG11201907923V A SG 11201907923VA SG 11201907923V A SG11201907923V A SG 11201907923VA SG 11201907923V A SG11201907923V A SG 11201907923VA SG 11201907923V A SG11201907923V A SG 11201907923VA
Authority
SG
Singapore
Prior art keywords
singapore
amino acid
acid sequence
international
antibody
Prior art date
Application number
SG11201907923VA
Inventor
Chong Kok Teo
Andre Boon Hwa Choo
Wee Joo Chng
Original Assignee
Agency Science Tech & Res
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Nat Univ Singapore filed Critical Agency Science Tech & Res
Publication of SG11201907923VA publication Critical patent/SG11201907923VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SLAMOIHarvest Plasma B ceiis Screening via FlOw cytometry agaibst MIL Mil and normal cell lines SPP3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT IiiimmommionotiolomonoloncicioniovoimIE (10) International Publication Number WO 2018/182529 Al (51) International Patent Classification: C07K 16/30 (2006.01) GO1N 33/574 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) A61K 47/64 (2017.01) A61P 35/02 (2006.01) (21) International Application Number: PCT/SG2018/050158 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201702572P 29 March 2017 (29.03.2017) SG (71) Applicants: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG). NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). (72) Inventors: TEO, Chong Kok; c/o Bioprocessing Tech- nology Institute (BTI), 20 Biopolis Way, Level 4 (Stem Cells), Centros, Singapore 138668 (SG). CHOO, Andre Boon Hwa; c/o Bioprocessing Technology Institute (BTI), 20 Biopolis Way, Level 4 (Stem Cells), Centros, Singapore 138668 (SG). CHNG, Wee Joo; c/o National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (54) Title: ANTI OLIGOSACCHARIDE ANTIBODY SLAMF7 (CD319) ecto-domain; 6 weekly immunizations Panel of Hybndomas (57) : An antigen-binding protein, or an antigen-binding fragment thereof that binds to a Lewis X type glycan on SLAMF7, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYTFTSYWIH; a VHCDR2 having the amino acid sequence EINPSNGRTNFNEKFKN and a VHCDR3 having the amino acid sequence VDYDEAY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence RSSKSLLHSNGITYLY, a VLCDR2 having the amino acid sequence QMSNLAS, and a VLCDR3 having the amino acid sequence AQNLELWT is provided. Methods of using the antibody for detecting or treating cancer, and a kit comprising the antibody are also provided. [Continued on next page] WO 2018/182529 Al MIDEDIMOMOIDEIREEM3111011110MOMEHOIS OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
SG11201907923VA 2017-03-29 2018-03-29 Anti oligosaccharide antibody SG11201907923VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201702572P 2017-03-29
PCT/SG2018/050158 WO2018182529A1 (en) 2017-03-29 2018-03-29 Anti oligosaccharide antibody

Publications (1)

Publication Number Publication Date
SG11201907923VA true SG11201907923VA (en) 2019-09-27

Family

ID=63676732

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907923VA SG11201907923VA (en) 2017-03-29 2018-03-29 Anti oligosaccharide antibody

Country Status (5)

Country Link
US (1) US11124579B2 (en)
EP (1) EP3601365A4 (en)
CN (1) CN110382546A (en)
SG (1) SG11201907923VA (en)
WO (1) WO2018182529A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
JP5340935B2 (en) * 2006-08-07 2013-11-13 アッヴィ・バイオセラピューティクス・インコーポレイテッド Method for treating multiple myeloma using combination therapy based on anti-CS1 antibody
CN101970498A (en) * 2007-10-25 2011-02-09 维文蒂阿生物技术公司 Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof
WO2010051391A1 (en) * 2008-10-31 2010-05-06 Facet Biotech Corporation Use of anti-cs1 antibodies for treatment of rare lymphomas
PT2740798T (en) * 2011-08-04 2017-03-13 Toray Industries Cancer treatment and/or prevention drug composition
WO2014153002A1 (en) 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
US10011657B2 (en) * 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
CN104558175B (en) * 2014-12-30 2017-02-22 安源医药科技（上海）有限公司 Reorganized chimeric antibody for resisting VEGF for people and preparation method and use of reorganized chimeric antibody

Also Published As

Publication number Publication date
US11124579B2 (en) 2021-09-21
US20200024359A1 (en) 2020-01-23
EP3601365A4 (en) 2021-01-13
WO2018182529A1 (en) 2018-10-04
EP3601365A1 (en) 2020-02-05
CN110382546A (en) 2019-10-25

Similar Documents

Publication Publication Date Title
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201808979UA (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
SG11201900703TA (en) Anti-annexin a2 monoclonal antibodies
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201811184UA (en) Lag -3 binding members
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201905460SA (en) Data unsealing with a sealing enclave
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201408347UA (en) Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201806284TA (en) Low pressure separator having an internal divider and uses therefor
SG11201407812SA (en) Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same